Even though the idea that amyloid B peptide accumulation is the primary event in the pathogenesis of Alzheimer's disease has become the leading hypothesis, the causal link between aberrant amyloid precursor protein processing and tau alterations in this type of dementia remains controversial. We further investigated the role of B-amyloid production/deposition in tau pathology and neuronal cell death in the mouse brain by crossing Tg2576 and VLW lines expressing human mutant amyloid precursor protein and human mutant tau, respectively. The resulting double transgenic mice showed enhanced amyloid deposition accompanied by neurofibrillary degeneration and overt neuronal loss in selectively vulnerable brain limbic areas. These findings challenge the idea that tau pathology in Alzheimer's disease is merely a downstream effect of amyloid production/deposition and suggest that reciprocal interactions between B-amyloid and tau alterations may take place in vivo. D
In the past decade, the idea that accumulation of amyloid h peptide (Ah) in the brain is the primary influence in Alzheimer's disease (AD) pathogenesis has become the leading hypothesis (Hardy and Higgins, 1992; Selkoe, 1991) . According to this theory, neurofibrillary tangle (NFT) formation and the loss of neurons and synapses in vulnerable regions that invariably accompanies Ah deposition in the human AD brain are said to be downstream events resulting from an imbalance between Ah production and Ah clearance.
The discovery of AD-causing mutations in the amyloid protein precursor (APP) and the presenilins 1 and 2 genes, along with the finding that all of these genetic defects enhance the proteolytic processing of APP to form Ah, is probably the strongest evidence favoring the amyloid cascade hypothesis (reviewed in (Selkoe, 1997) ).
The recent finding that active immunization against h-amyloid is associated with a reduction of amyloid deposits, neuritic pathology and gliotic changes in human AD brains provides further evidence for the validity of the amyloid cascade hypothesis (Hardy and Selkoe, 2002) , even though at this point very important safety issues regarding this therapeutic approach need to be addressed (Schenk, 2002) .
A role for Ah in neurofibrillary degeneration is also supported by recent findings showing that coexpression of human mutant tau and APP in the mouse brain results in increased NFT formation, whereas amyloid deposition remains essentially unaltered (Lewis et al., 2001) . Moreover, intracerebral injection of fibrillar Ah42 in P301L mutant tau transgenic (Tg) mice caused a fivefold increase in the number of NFT, favoring the hypothesis that fibrillar Ah can accelerate NFT formation in vivo (Gotz et al., 2001) .
All together, the above findings suggest that altered APP processing would precede tau alterations in the pathogenesis of 
